| Autor: |
Jacobs, Edwin M., Peters, Frances C., Luce, James K., Zippin, Calvin, Wood, David A. |
| Zdroj: |
JAMA: Journal of the American Medical Association; February 1968, Vol. 203 Issue: 6 p392-398, 7p |
| Abstrakt: |
Eighty-six patients (37 with Hodgkin's disease, 37 with lymphosarcoma, and 12 with reticulum cell sarcoma) were randomized and treated with either a single dose of mechlorethamine hydrochloride (0.4 mg/kg of body weight, given intravenously) followed by daily maintenance with chlorambucil (given orally), or a loading dose of cyclophosphamide (40 mg/kg of body weight, given intravenously) followed by daily maintenance with cyclophosphamide (given orally). No significant difference was observed between these two regimens in frequency of objective tumor response: 45% of patients who received mechlorethamine and 57% who received cyclophosphamide had an objective response. Marked alopecia was the only significant difference in toxic effects, occurring in 36% of the patients receiving cyclophosphamide and in one patient receiving mechlorethamine. A slight plateletsparing effect of cyclophosphamide over mechlorethamine and chlorambucil was not considered clinically significant. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
